glp 1 agonist in ckd Glucagon-like peptide-1 receptor agonists diabetic kidney disease: A review of their kidney and heart protection Repurposing Diabetes Therapies in CKD:

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of highfat diet

Complete information on authors, methodology and conflicts of interest is available in the published paper

This confounded efforts to establish whether it had insulin secretory properties (Marks 2020)

A rigorously designed study reported an imprecise estimate favouring semaglutide [55], but events in that study were scarce, highlighting a need for further investigation as data continue to accumulate

6.8% in the triple therapy and conventional therapy arms respectively ( p = 0.0006)

Other GLP-1 medications include liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)